Workflow
ZBH Stock Might Rise Following FDA Nod for Knee Implant Component
ZBHZimmer Biomet(ZBH) ZACKS· ZACKS·2024-12-05 13:55

Company Developments - Zimmer Biomet Holdings Inc (ZBH) received FDA 510(k) clearance for its Persona SoluTion PPS Femur, a total knee implant component designed for patients with sensitivities to bone cement and/or metal [1] - The company expects to commercially launch Persona SoluTion PPS Femur in the United States in Q1 2025 [1] - ZBH recently received FDA Premarket Approval Application Supplement approval for the Oxford Cementless Partial Knee, making it the only FDA-approved cementless partial knee implant in the United States [8] Product Details - Persona SoluTion PPS Femur combines cementless fixation with PPS coating, providing initial scratch fit stability and supporting biological fixation through bony growth [5] - The implant minimizes common metal sensitizers by combining with Persona OsseoTi tibia and Vivacit-E Highly Crosslinked Polyethylene (HXLPE) [6] - The implant is made of Tivanium (Ti-6Al-4V) alloy with over 17 years of clinical use, treated with the Ti-Nidium Surface Hardening Process [6] Market Performance - ZBH shares moved 0.1% lower to 110.62followingtheannouncement[2]Thecompanyhasamarketcapitalizationof110.62 following the announcement [2] - The company has a market capitalization of 22.09 billion [3] - ZBH shares have lost 4.5% in the past year, compared to the industry's 21% growth [9] Financial Performance - ZBH's earnings surpassed estimates in three of the trailing four quarters, with an average surprise of 1.76% [3] Industry Outlook - The global knee replacement market is expected to reach $16.99 billion by 2031, growing at a CAGR of 5.67% during 2024-2031 [7] - Key growth drivers include rising incidence of osteoarthritis and increasing demand for joint replacement surgeries [7]